At the news
? MIXEDIMPACT 6/10 DEFA14A filed Mar 17, 2026 at 17:29 ET
OraSure Technologies filed a definitive proxy statement (DEFA14A) in response to an activist campaign by Altai Capital, which is pushing for board representation to force a sale of the company. OraSure's management defends its transformation strategy, highlighting upcoming product launches, cost reductions, and a $40 million share buyback, while accusing Altai's founder of seeking personal control rather than shareholder value.
- OraSure is facing a proxy contest from activist investor Altai Capital, which seeks board representation to push for a sale.
- The company has rejected Altai's demands, stating it is at a strategic inflection point with key product launches in 2026.
- OraSure highlights operational progress: 40% workforce reduction, 37% SG&A cost cut since 2022, and ~260 bps gross margin expansion.
- The company submitted FDA applications for two high-impact STI tests targeting a $2B market.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access